Received: 4 October 2022
Accepted: 22 February 2023
First Online: 7 March 2023
: Study approval was obtained by the Medical Ethical Committee (METC) and the Board of Zuyderland Medical Centre in Heerlen, the Netherlands. Number: METCZ20200126. All methods were carried out in accordance with relevant guidelines and regulations. All patients provided written informed consent for the use of their data for this study.
: Not applicable.
: SR reports personal fees from AbbVie, personal fees from Eli Lilly, grants and personal fees from MSD, personal fees from Novartis, personalfees from Sanofi, personal fees from UCB, outside the submitted work. RLMM reports personal fees from Boehringer Ingelheim, personal fees from Galapagos, outside the submitted work. Rest all authors declare no competing interests.